TCN e-Systems has introduced product enhancements that include mobile connectivity from a smartphone device. The core technology, TrialCentralNetSM, has served as the infrastructure for global and domestic clinical studies, and users are now able to make more rapid business decisions regarding trial management through broader access to real-time recruitment metrics.
“We’ve created a smartphone app to address the needs of clinical teams that rely on our tools for readily accessible, real-time information,” said Sarah Mandracchia, director of data management. “The smartphone app provides access to study-goal information, enrollment numbers, key dates, country information, and media metrics, and study teams can now assess key data and make decisions on the go through their iPhone® or Blackberry®.”
Among the latest enhancements to Version 5.2 is the addition of 11 new languages to the product’s language library.
“With the addition of these languages, we now cover 80 percent of clinical research professionals in their native languages, which will allow site personnel to focus on recruitment efforts and data management. User satisfaction and compliance are certainly expected to benefit as well," Mandracchia said.
The TrialCentralNetSM language library now includes Chinese, Dutch, English, French, German, Hindi, Italian, Japanese, Polish, Portuguese, Russian, and Spanish.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.